Orchid Pharma

Why is Orchid Pharma Ltd falling/rising?

As of 17-Aug, Orchid Pharma Ltd's stock price is at 999.00, down 4.59% and underperforming the sector. The stock has shown a negative trend recently, with decreased trading volume and significant price drops, indicating a shift in market sentiment.

As of 17-Aug, Orchid Pharma Ltd's stock price is falling, currently at 999.00, which reflects a decrease of 48.1 (-4.59%). The stock has underperformed the sector by 4.29% today and opened with a loss of 4.5%. It reached an intraday low of Rs 942, marking a significant drop of 10.04%. Additionally, the stock's delivery volume has decreased by 39.21% compared to the 5-day average, indicating a decline in investor participation.<BR><BR>In the short term, the stock has shown a negative trend, with a 7.21% drop over the past week and a 4.09% decline over the past month. Despite its strong performance year-to-date with a 31.59% increase and a 33.48% rise over the past year, the recent price movements suggest a shift in market sentiment. The stock remains above its 50-day, 100-day, and 200-day moving averages but is below its 5-day and 20-day moving averages, which may indicate a weakening momentum.<BR><BR>Overall, the combination of today's significant price drop, reduced trading volume, and recent underperformance relative to the sector contributes to the current decline in Orchid Pharma Ltd's stock price.

Which are the latest news on Orchid Pharma?

Should I buy, sell or hold Orchid Pharma Ltd?

Who are in the management team of Orchid Pharma?

The management team of Orchid Pharma includes Manish Dhanuka (Managing Director), Mridul Dhanuka (Whole-time Director), Ram Gopal Agarwal (Non-Executive Chairman), and Marina Peter (Company Secretary). The board also features Independent Directors Tanu Singla, Dharam Vir, Mudit Tandon, and Manoj Goyal.

The management team of Orchid Pharma includes the following individuals:<BR><BR>1. **Manish Dhanuka** - Managing Director<BR>2. **Mridul Dhanuka** - Whole-time Director<BR>3. **Ram Gopal Agarwal** - Chairman (Non-Executive)<BR>4. **Marina Peter** - Company Secretary & Compliance Officer<BR><BR>Additionally, there are several Independent Directors on the board:<BR><BR>- **Tanu Singla**<BR>- **Dharam Vir**<BR>- **Mudit Tandon**<BR>- **Manoj Goyal**<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Orchid Pharma do?

Orchid Pharma Ltd is a leading Indian pharmaceutical company specializing in the Pharmaceuticals & Biotechnology sector, with a market cap of INR 10,204 Cr and reported net sales of 238 Cr and net profit of 24 Cr for the quarter ending March 2026. Key financial metrics include a P/E ratio of 368.00 and a debt-equity ratio of 0.22.

Overview: <BR>Orchid Pharma Ltd is a leading pharmaceutical company in India, operating in the Pharmaceuticals & Biotechnology industry and categorized as a Small Cap.<BR><BR>History: <BR>Orchid Pharma was incorporated in an unspecified year and has undergone various status changes. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 238 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 24 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 10,204 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 368.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.22 <BR>Return on Equity: 2.09% <BR>Price to Book: 7.89<BR><BR>Contact Details: <BR>Address: Orchid Towers Nungambakkam, 313 Valluvar Kottam High Road Chennai Tamil Nadu : 600034 <BR>Tel: 91-44-28211000/28230000 <BR>Email: corporate@orchidpharma.com <BR>Website: http://www.orchidpharma.com

Who are the peers of the Orchid Pharma?

Orchid Pharma's peers include Akums Drugs, Viyash Scientifi, Blue Jet Health, Sanofi Consumer, P & G Health Ltd, Strides Pharma, Aarti Pharma, Sanofi India, and Senores Pharma. In terms of management risk, growth, and capital structure, Orchid Pharma is rated below average compared to its peers, with a 1-year return of 34.62%.

Peers: The peers of Orchid Pharma are Akums Drugs, Viyash Scientifi, Blue Jet Health, Sanofi Consumer, P & G Health Ltd, Strides Pharma, Aarti Pharma, Sanofi India, and Senores Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanofi Consumer, P & G Health Ltd, and Sanofi India, while Average management risk is found at Akums Drugs, Strides Pharma, Aarti Pharma, and Senores Pharma. Below Average management risk is present at Viyash Scientifi and Orchid Pharma. Growth is rated as Excellent for Senores Pharma, Good for Viyash Scientifi and Strides Pharma, and Average for Akums Drugs, Aarti Pharma, and Orchid Pharma, while Below Average growth is seen at Blue Jet Health, Sanofi Consumer, P & G Health Ltd, and Sanofi India. Capital Structure is rated as Excellent for Akums Drugs, Blue Jet Health, Sanofi Consumer, P & G Health Ltd, and Aarti Pharma, while Average is noted for Strides Pharma and Senores Pharma, and Below Average for Viyash Scientifi, Orchid Pharma, and Sanofi India.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Senores Pharma at 119.04%, while the lowest is Sanofi India at -35.74%. Orchid Pharma's 1-year return of 34.62% is significantly higher than Sanofi India's but lower than Senores Pharma's. Additionally, Sanofi India and Strides Pharma have negative six-month returns.

How big is Orchid Pharma?

As of 14th August, Orchid Pharma Ltd has a market capitalization of 9,966.06 Cr, with recent net sales of 811.33 Cr and a net profit of 20.36 Cr. Shareholder's funds are 1,267.29 Cr and total assets amount to 1,687.91 Cr as of March 2025.

As of 14th August, Orchid Pharma Ltd has a market capitalization of 9,966.06 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest 4 quarters, Orchid Pharma reported Net Sales of 811.33 Cr and a Net Profit of 20.36 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 1,267.29 Cr and Total Assets of 1,687.91 Cr.

When is the next results date for Orchid Pharma Ltd?

The next results date for Orchid Pharma Ltd is 14 August 2026.

The next results date for Orchid Pharma Ltd is scheduled for 14 August 2026.

Are Orchid Pharma Ltd latest results good or bad?

Orchid Pharma Ltd's latest Q4 FY26 results show a significant recovery in profitability, with a net profit of ₹23.78 crores and improved operating margins. However, the stock has underperformed over the past year, and high valuation metrics raise concerns about sustainability, suggesting investors should be cautious.

Orchid Pharma Ltd's latest results for Q4 FY26 indicate a significant recovery in profitability, marking a positive turnaround after two consecutive quarters of losses. The consolidated net profit reached ₹23.78 crores, which is a remarkable increase of 288.58% compared to the previous quarter. This also represents a 6.68% increase year-on-year. Additionally, net sales hit an all-time quarterly high of ₹237.61 crores, reflecting a sequential growth of 14.64%, although year-on-year growth was minimal at 0.05%.<BR><BR>The operating margin improved notably to 11.31%, up from just 0.76% in the previous quarter, indicating better operational efficiency. The profit after tax (PAT) margin also recovered to 9.59% from a negative margin of -5.86% in Q3 FY26.<BR><BR>However, despite these positive results, the company faces challenges. The stock has underperformed over the past year, declining 1.88%, and is down 29.08% over the last two years. The high valuation metrics, with a trailing P/E ratio of 140.23 times compared to the sector average of 34 times, raise concerns about sustainability and investor expectations.<BR><BR>In summary, while the latest quarter's results show strong recovery and improved profitability, the underlying issues related to valuation and past performance suggest that investors should approach with caution.

Is Orchid Pharma technically bullish or bearish?

As of December 4, 2025, the trend has shifted to mildly bullish, supported by daily moving averages and a bullish RSI on the monthly chart, though mixed signals from the MACD and Bollinger Bands indicate divergence between short-term and long-term trends.

As of 4 December 2025, the technical trend has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating bullish momentum. The weekly MACD is also mildly bullish, while the monthly MACD remains bearish, suggesting mixed signals across time frames. The RSI shows a bullish signal on the monthly chart, but no signal on the weekly, indicating potential strength in the longer term. Bollinger Bands are bullish on the weekly but mildly bearish on the monthly, adding to the mixed outlook. Overall, the strength of the bullish stance is moderate, with key indicators showing divergence between short-term and long-term trends.

How has been the historical performance of Orchid Pharma?

Orchid Pharma has shown significant financial improvement from March 2023 to March 2025, with net sales increasing from 665.90 Cr to 921.93 Cr, and consolidated net profit rising from 46.32 Cr to 99.66 Cr, indicating strong recovery and growth. Total assets and liabilities grew in tandem, while cash flow from operations improved markedly.

Answer:<BR>The historical performance of Orchid Pharma shows a significant improvement in financial metrics over the years, particularly from March 2023 to March 2025.<BR><BR>Breakdown:<BR>Orchid Pharma's net sales have steadily increased from 665.90 Cr in March 2023 to 921.93 Cr in March 2025, reflecting a robust growth trajectory. The total operating income followed a similar trend, rising from 665.90 Cr to 921.93 Cr during the same period. The company's operating profit (PBDIT) also improved significantly, increasing from 103.05 Cr in March 2023 to 144.65 Cr in March 2025, although the operating profit margin slightly decreased from 12.56% to 12.71%. Profit before tax rose from 55.25 Cr to 95.56 Cr, and profit after tax increased from 55.25 Cr to 95.76 Cr, indicating a strong recovery from previous losses. The consolidated net profit showed a remarkable increase from 46.32 Cr in March 2023 to 99.66 Cr in March 2025. On the balance sheet, total assets grew from 1,225.21 Cr to 1,687.91 Cr, while total liabilities increased from 1,225.21 Cr to 1,687.91 Cr, reflecting a balanced growth in both assets and liabilities. Cash flow from operating activities improved, with a net cash inflow of 17.00 Cr in March 2025 compared to a net outflow of 19.00 Cr in March 2024. Overall, Orchid Pharma's financial performance demonstrates a strong recovery and growth in key areas over the past few years.

Is Orchid Pharma overvalued or undervalued?

As of July 21, 2025, Orchid Pharma is considered overvalued with a PE ratio of 36.74 and an EV to EBITDA of 31.21, significantly higher than its peers, and has underperformed with a year-to-date return of -60.27% compared to the Sensex's gain of 5.20%.

As of 21 July 2025, Orchid Pharma's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its relative valuation. Despite this change, the company appears to be overvalued based on its current financial metrics. The PE ratio stands at 36.74, while the EV to EBITDA ratio is 31.21, both of which are significantly higher than many of its peers. Additionally, the PEG ratio of 4.17 suggests that the stock may be priced too high relative to its growth prospects.<BR><BR>In comparison to its peers, Sun Pharma has a PE of 35.52 and an EV to EBITDA of 25.11, while Cipla shows a more attractive valuation with a PE of 22.6 and an EV to EBITDA of 15.65. These comparisons highlight that Orchid Pharma's valuation is not justified when considering its earnings and growth potential. Furthermore, the company's year-to-date return of -60.27% starkly contrasts with the Sensex's gain of 5.20%, reinforcing the notion that Orchid Pharma is currently overvalued.

Who are the top shareholders of the Orchid Pharma?

The top shareholders of Orchid Pharma include Dhanuka Laboratories Limited with a 69.84% stake, mutual funds at 18.79% (led by Quant Small Cap Fund at 6.83%), Foreign Institutional Investors at 2.69%, and individual investors holding 5.11%. There are no pledged promoter holdings reported.

The top shareholders of Orchid Pharma include Dhanuka Laboratories Limited, which holds the highest promoter stake at 69.84%. Additionally, mutual funds collectively hold 18.79% of the shares, with the Quant Mutual Fund - Quant Small Cap Fund being the largest public shareholder at 6.83%. Foreign Institutional Investors (FIIs) have a stake of 2.69%, and individual investors hold 5.11% of the shares. There are no pledged promoter holdings reported.

Has Orchid Pharma declared dividend?

Orchid Pharma has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of September 13, 2012. However, the dividend yield is 0%, and total returns have shown significant volatility, with notable gains over the 5-year period despite recent declines.

Orchid Pharma Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3<BR>- Ex-date: 13 Sep 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -59.45%, the dividend return was 0%, resulting in a total return of -59.45%.<BR><BR>For the 1-year period, the price return was -32.95%, the dividend return was 0%, leading to a total return of -32.95%.<BR><BR>Over the 2-year period, the price return was 72.37%, with a dividend return of 0%, resulting in a total return of 72.37%.<BR><BR>In the 3-year period, the price return was 137.39%, the dividend return was 0%, culminating in a total return of 137.39%.<BR><BR>For the 4-year period, the price return was -49.4%, with a dividend return of 0%, leading to a total return of -49.4%.<BR><BR>In the 5-year period, the price return was 13462.86%, with a dividend return of 0%, resulting in a total return of 13462.86%.<BR><BR>Overall, while Orchid Pharma has declared a dividend, the dividend yield remains at 0%, indicating that the dividend has not contributed to returns in recent periods. The total returns show significant volatility, with substantial gains over longer periods, particularly in the 5-year timeframe.